Acorda Therapeutics (ACOR) Reports Q1 Loss of $0.69
Tweet
Share
E-mail
Get Alerts ACOR Hot Sheet
Join SI Premium – FREE
Acorda Therapeutics (NASDAQ: ACOR) reported Q1 EPS of ($0.69), versus $0.00 reported last year. Revenue for the quarter came in at $22.25 million versus the consensus estimate of $0 .
For earnings history and earnings-related data on Acorda Therapeutics (ACOR) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Tesla to launch Cybercab in Austin this month - report
- CalPrivate Bank names Andra Frazier as chief credit officer
- Yalla Group Limited (YALA) Reports Q2 EPS of $0.24
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
